

**EXPRESS MAIL NO.: EV335858058US**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of:	Bolognesi et al.	Confirmation No.:	To be assigned
Application No.:	To be assigned (continuation of U.S. Application No. 08/484,223 filed June 7, 1995)	Art Unit:	To be assigned
Filed:	Herewith	Examiner:	To be assigned
For:	ISOLATED PEPTIDES DERIVED FROM HUMAN IMMUNODEFICIENCY VIRUS TYPES 1 AND 2 CONTAINING FUSION INHIBITORY DOMAINS	Attorney Docket No.:	7872-109-999

**PRELIMINARY AMENDMENT**

**Mail Stop PATENT APPLICATION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In advance of prosecution, please enter the amendments set forth below and consider the remarks which follow in connection with the above-identified application. Applicants submit concurrently herewith: (a) a Request for Filing Continuation Application and Fee Transmittal (in duplicate); (b) a Utility Patent Application Transmittal (CON); (c) a Declaration and Power of Attorney (executed, copy from U.S. Application No. 08/470,896 filed June 6, 1995); (d) a copy of U.S. Application No. 08/484,223 as filed June 7, 1995; (e) a Sequence Listing on two compact discs labeled "Copy 1" and "Copy 2"; and (f) a Statement Under 37 C.F.R. § 1.821.

**Amendments to the Specification** begin on page 2 of this paper.

**Remarks/Arguments** begin on page 17 of this paper.